title: The biological evaluation of ADMA/SDMA and eNOS in patients with ACHF.
abstract: The aim of this study was to investigate the effects of acute pharmacological treatment on the plasma levels of l-arginine, asymmetrical dimethylarginine (ADMA), and symmetrical dimethylarginine (SDMA). We also investigated the related effects on endothelial nitric oxide synthase (eNOS) expression and activity and cytochrome c oxidase activity in the primary blood mononuclear cells (PBMCs) isolated from patients with acute congestive heart failure (ACHF). Compared to pre-treatment values, ADMA, SDMA, and l-arginine plasma levels were significantly higher after pharmacological treatment (ADMA, 0.82 versus 0.43 µM; SDMA, 1.52 versus 1.12 µM; l-arginine, 1.78 versus 1.29 µM; p < 0.01. In addition, the levels of eNOS expression and activity were decreased after pharmacological treatment, while cytochrome c oxidase activity resulted in higher O2-production. In the PBMCs isolated from patients with acute congestive heart failure (ACHF) and impaired renal function, higher SDMA and ADMA levels were more evident after therapy, as were reduced expression and activity of eNOS. Increased O2- produced after treatment may be involved in impaired recovery of cardiac function associated with higher plasma levels of SDMA.
authors.affiliation: Dept of Medicine and Science of aging, G D'Annunzio, Via dei Vestini, 31 66123 Chieti, Italy. l.speranza@unich.it
authors.forename: Lorenza
authors.initials: L
authors.lastname: Speranza
authors.forename: Mirko
authors.initials: M
authors.lastname: Pesce
authors.forename: Sara
authors.initials: S
authors.lastname: Franceschelli
authors.forename: Tonino
authors.initials: T
authors.lastname: Bucciarelli
authors.forename: Sabina
authors.initials: S
authors.lastname: Gallina
authors.forename: Graziano
authors.initials: G
authors.lastname: Riccioni
authors.forename: Antonia
authors.initials: A
authors.lastname: Patruno
authors.forename: Mario
authors.initials: M
authors.lastname: Felaco
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000378:metabolism; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood*; D001219:Aspartate Aminotransferases / Q000378:metabolism; D015153:Blotting, Western; D002851:Chromatography, High Pressure Liquid; D004077:Digoxin / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004452:Echocardiography; D003576:Electron Transport Complex IV / Q000378:metabolism; D005260:Female; D006333:Heart Failure / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D007677:Kidney Function Tests; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D010100:Oxygen / Q000378:metabolism
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics; C024917:symmetric dimethylarginine; C018524:N,N-dimethylarginine; D004077:Digoxin; D001120:Arginine; D052250:Nitric Oxide Synthase Type III; D003576:Electron Transport Complex IV; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D010100:Oxygen